Zealand Pharma
Tracked across 2 events · 12 articles · First seen Apr 19, 2026 · Last active May 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Zealand Pharma has announced the initiation of a DKK 1.3 billion (USD 200 million) share buy-back program, effective from May 7, 2026, to October 31, 2026. The program, managed by Danske Bank, aims to meet…
Impact: Zealand Pharma initiated a DKK 1.3 billion share buy-back program, demonstrating strong financial health and a commitment to returning capital to shareholders while investing in its metabolic health pipeline.
May 07, 2026 · 6 articles
Business
PatentVest, a division of MDB Capital Holdings, released a comprehensive report titled 'The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market' on May 8, 2026. The report analyzes…
Impact: Zealand Pharma is mentioned as an emerging player in the race to define the next generation of obesity therapeutics.
May 08, 2026 · 6 articles
100
Zealand Pharma initiates share buy-backZealand Pharma Initiates...
80
Zealand Pharma expects milestone payments RocheZealand Pharma Initiates...
30
Danske Bank appointed lead manager Zealand PharmaZealand Pharma Initiates...
NEWSDESK
Track Zealand Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard